Elutia Inc. Class A Common Stock (ELUT) Stock Price

ELUTStock

$0.79−11.78%52W

Market Cap$35.17M

P/E0.66x

PEG Ratio—

Div yield—

Beta0.96

ELUT Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-40.26%

Price vs S&P 500 (4W)-5.64%

VGM Score48.32

P/E Ratio (Annual)0.66x

Book Value / Share (Quarterly)$0.36

P/TBV (Annual)1.13x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-37.01%

Cash Flow / Share (Quarterly)$-1.04

Price vs S&P 500 (YTD)2.65%

Gross Margin (TTM)57.82%

Net Profit Margin (TTM)426.93%

EPS (TTM)$1.22

10-Day Avg Trading Volume0.15M

EPS Excl Extra (TTM)$1.22

Revenue Growth (5Y)-22.04%

EPS (Annual)$1.29

ROI (Annual)192.90%

Gross Margin (Annual)53.66%

Net Profit Margin (5Y Avg)-11.71%

Cash / Share (Quarterly)$0.45

P/E Basic Excl Extra (TTM)0.68x

Revenue Growth QoQ (YoY)-61.25%

P/E Normalized (Annual)0.66x

ROA (Last FY)85.61%

Revenue Growth TTM (YoY)-48.76%

EBITD / Share (TTM)$-0.57

Operating Margin (TTM)-214.87%

Cash Flow / Share (Annual)$-1.09

P/B Ratio2.23x

P/B Ratio (Quarterly)2.75x

Net Income / Employee (Annual)$2,135,200

EV / Revenue (TTM)1.26x

Net Interest Coverage (TTM)-1.87x

ROA (TTM)108.72%

EPS Incl Extra (Annual)$1.29

Current Ratio (Annual)2.22x

Quick Ratio (Quarterly)1.58x

3-Month Avg Trading Volume0.16M

52-Week Price Return-11.78%

P/E Incl Extra (TTM)0.68x

Revenue / Employee (TTM)$485,400

Tangible BV / Share (Quarterly)$0.33

P/S Ratio (Annual)2.86x

Asset Turnover (Annual)0.20x

52-Week High$1.39

Operating Margin (5Y Avg)-115.31%

EPS Excl Extra (Annual)$1.29

CapEx CAGR (5Y)24.00%

26-Week Price Return-30.35%

Quick Ratio (Annual)2.03x

13-Week Price Return-16.42%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)1.77x

Enterprise Value$15.27M

Revenue / Share Growth (5Y)-41.06%

Asset Turnover (TTM)0.25x

Revenue / Employee (Annual)$491,700

Inventory Turnover (Annual)1.75x

Pretax Margin (Annual)-129.00%

Cash / Share (Annual)$0.85

3-Month Return Std Dev59.45%

Gross Margin (5Y Avg)41.02%

Net Income / Employee (TTM)$2,072,300

ROE (Last FY)192.90%

Net Interest Coverage (Annual)-4.06x

EPS Basic Excl Extra (Annual)$1.29

Receivables Turnover (TTM)5.29x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$1.22

Receivables Turnover (Annual)6.13x

ROI (TTM)253.28%

P/S Ratio (TTM)2.90x

Pretax Margin (5Y Avg)-120.13%

Revenue / Share (Annual)$0.30

Tangible BV / Share (Annual)$0.61

Price vs S&P 500 (52W)-27.31%

P/E Ratio (TTM)0.68x

Year-to-Date Return14.57%

5-Day Price Return0.89%

EPS Normalized (Annual)$1.29

ROA (5Y Avg)-47.04%

Net Profit Margin (Annual)434.23%

Month-to-Date Return0.51%

Cash Flow / Share (TTM)$-1.72

EBITD / Share (Annual)$-0.58

Operating Margin (Annual)-218.91%

LT Debt / Equity (Annual)0.00x

P/E Excl Extra (TTM)0.68x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$1.22

P/TBV (Quarterly)2.93x

P/B Ratio (Annual)1.07x

Inventory Turnover (TTM)1.30x

Pretax Margin (TTM)-184.24%

Book Value / Share (Annual)$0.65

Price vs S&P 500 (13W)-19.11%

Beta0.96x

Revenue / Share (TTM)$0.27

ROE (TTM)253.28%

52-Week Low$0.50

vGradeB

gGradeF

mGradeC

vgmGradeC

ELUT Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 13, 2026	-$0.15	-$0.17	-13.33%(-$0.02)
Q1 2026	May 14, 2026	-$0.15	-$0.17	-13.33%(-$0.02)
Q4 2025	Mar 11, 2026	-$0.14	$1.48	+1157.14%(+$1.62)
Q3 2025	Nov 6, 2025	-$0.15	-$0.09	+41.94%(+$0.07)
Q2 2025	Aug 14, 2025	-$0.17	-$0.23	-35.29%(-$0.06)

ELUT Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.14

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ELUTElutia Inc. Class A Common Stock	B	F	C	2.9x	-48.8%	57.8%	—	$0.79
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74

About Elutia Inc. Class A Common Stock

Elutia Inc (formerly Aziyo Biologics Inc) is a commercial-stage regenerative medicine company that develops products to improve surgical outcomes and reduce complications associated with implantable medical devices. The company operates three segments—Device Protection, Women's Health, and Cardiovascular—with Women's Health as its primary revenue driver. Its product portfolio addresses unmet clinical needs including scar tissue formation, implant rejection, capsular contraction, and device-related complications.